Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism

PHASE2TerminatedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
AlcoholismAlcohol DependenceAlcohol Abuse
Interventions
DRUG

Topiramate

Topiramate will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses 300 mg topiramate.

DRUG

Zonisamide

Zonisamide will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 400 mg of zonisamide.

DRUG

Levetiracetam

Levetiracetam will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 mg levetiracetam capsules.

DRUG

Sugar Pill

Matched placebo will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14.

Trial Locations (1)

02118

Boston University School of Medicine, Boston

Sponsors
All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

Boston Medical Center

OTHER

NCT00862563 - Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism | Biotech Hunter | Biotech Hunter